Ibrahim Musa Kida

Cognitive function in HIV-seropositive Nigerians without AIDS

Studies of cognitive function in individuals with HIV infection who remain relatively asymptomatic have shown widely variable estimates of impairment in different races and countries. Limited data exist on the impact of early asymptomatic HIV infection on cognition in developing nations, and indeed none from Nigeria. Hence, this cross-sectional study sets out to determine whether there are differences between Nigerian asymptomatic HIV-seropositive and HIV-seronegative subjects, and whether such differences: if any, could be explained by the degree of immunosuppression (i.e. CD4 cell count). A selected population of 60 heterosexual asymptomatic treatment-naive HIV-positive subjects were administered the Community Screening Instrument for Dementia (CSI-D) to assess language, memory, registration, attention and calculation, recall, praxis and orientation. HIV positives differed from individually matched control subjects in certain measures of language expression, registration, attention and calculation, orientation to time, motor response and total CSI-D scores. The CD4 cell count of the HIV-seropositive subjects had no significant correlation with the cognitive test scores.

Risk factors for hepatitis C virus sero-positivity among haemodialysis patients receiving care at kidney centre in a tertiary health facility in Maiduguri, Nigeria.

Hepatitis C virus (HCV) is an important health care problem in haemodialysis. Hepatitis C virus is both a cause and complication of kidney diseases. Yet there are limited information on antibody against HCV in patients on haemodialysis. The purpose of this study was to determine the prevalence of anti-HCV and the risk factors associated with HCV infection in a cohort of 100 participants on haemodialysis. They were consecutively recruited into the study, anti-HCV testing was made by the 3rd-generation ELISA System (C-100, C-33c, C-22). The prevalence of HCV antibody was 15%, risk factors associated with HCV antibody were history of blood transfusion and duration of session of haemodialysis; the risk increased with increased with the number of blood transfusion and seasons of haemodialysis. The observed high prevalence of HCV antibody among patients on haemodialysis reflect the quality of healthcare services and the standards of infection control practices in our haemodialysis units. Routine screening for HCV should be done before blood transfusion using third generation ELISA assays with high sensitivity and specificity. Safety measures should be taken in our haemodialysis units to prevent cross infection among patients and staffs. These safety measures include; discarding syringes, needles, gloves, bloodlines and dialysers after single use, and the use of sterile dressings on each patient visit.

Changes in Lipid Profiles and Other Biochemical Parameters in HIV-1 Infected Patients Newly Commenced on HAART Regimen.

Abnormalities of lipid metabolism are common in human immunodeficiency virus (HIV)-infected patients and tend to be accentuated in those receiving antiretroviral therapy, particularly with protease inhibitors (PIs). However, there is a dearth of information on serum lipid profiles and biochemical parameters among treatment-naive HIV-positive patients in our environment. We found that after 24 months of highly active antiretroviral therapy (HAART), there was a significant increase in serum lipids. After 24 months of HAART, renal impairment was associated with a low increase in mean HDL and a high increase in triglycerides (TG). In conclusion, abnormality of serum lipid is common and showed female preponderance among treatment-naive HIV patients in our environment. Patients with HIV infection on HAART should be screened for lipid disorders given their high prevalence as observed in this study, because of its potential for morbidity and mortality in patients on HAART.

Evaluating Total Lymphocyte Counts and Other Hematological Parameters as a Substitute for CD4 Counts in the Management of HIV Patients in Northeastern Nigeria

This study was designed to validate or refute the reliability of total lymphocyte count (TLC) and other hematological parameters as a substitute for CD4 cell counts. Participants consisted of two groups, including 416 antiretroviral naive (G1) and 328 antiretroviral experienced (G2) patients. CD4+ T cell counts were performed using a Cyflow machine. Hematological parameters were analyzed using a hematology analyzer. The median ± SEM CD4 count (range) of participants in G1 was 199 ± 10.9 (5–1840 cells/µL) and the median ± SEM TLC (range) was 1. 61 ± 0.05 (0.07–6.63 × 103/µL). The corresponding values among G2 were 421 ± 15.8 (13–1801) and 2.13 ± 0.04 (0.06–5.58), respectively. Using a threshold value of 1.2 × 103/µL for TLC alone, the sensitivity of G1 was 88.4% (specificity (SP) 67.4%, the positive predictive value (PPV) 53.5% and negative predictive value (NPV) of 93.2% for CD4 < 200 cells/µL, the sensitivity for G2 was 83.3%, SP 85.3%, PPV 23.8%, and NPV of 93.2%. Using multiple parameters, including TLC < 1.2 × 103/µL, hemoglobin < 10 g/dL, and platelets < 150 × 103/L, the sensitivity increased to 96.0% (SP, 82.7%; PPV, 80%; NPV, 96.7%) among G1, while no change was observed in the G2 cohort. TLC < 1.2 × 103/µL alone is an insensitive predictor of CD4 count of , 200 cells/µL. Incorporating hemoglobin < 10 g/dL, and platelets < 150 × 103/L enhances the ability of TLC < 1.2 × 103/µL to predict CD4 count < 200 cells/µL among the antiretroviral-naive cohort. We recommend the use of multiple, inexpensively measured hematological parameters in the form of an algorithm for predicting CD4 count level.

Hepatic transaminase and alkaline phosphatase enzyme levels in HIV/HBV co‑infected and HIV mono‑infected patients in Maiduguri, Nigeria

BACKGROUND Studies have shown that HIV-HBV co-infected patients have an increased risk of liver-related morbidity and mortality compared to their HIV-mono-infected counterparts. Furthermore, it has been reported that HIV-HBV co-infected patients have a significantly high incidence of drug-induced hepatotoxicity following commencement of HAART than HIV-mono-infected patients. OBJECTIVES To compare the levels of aspartate amino transferase (AST), alanine amino transferase (ALT) and alkaline phosphatase (ALKPO 4 ) enzyme levels between HAART naïve HIV-HBV co-infected patients and their HIV-mono-infected counterparts. MATERIALS AND METHODS A cross-sectional descriptive study in which 142 newly diagnosed HIV/HBV co-infected and HIV mono-infected adults were investigated for alkaline aminotransferase, aspartate aminotransferase and alkaline phosphatase enzyme levels. RESULTS The study subjects comprised of 80 (56.3%) females and 62 (46.7%) males. The age range of the study population was 15-65 years. The mean ages of male and female subjects were 45.5 ± 10.5 years and 39.1 ± 7.5 years respectively ( P < 0.05). Sixty-three (44.4%) study subjects were HIV/HBV co-infected while 79 (55.6%) were HIV mono-infected. The mean ALT enzyme level of HIV/HBV co-infected subjects was significantly higher than that of HIV mono-infected ones i.e., 42.12 IU/l vs. 27.86 IU/l, ( P = 0.038). However, there was no statistically significant difference in the mean AST (30.14 IU/l vs. 29.09 IU/l, P = 0.893) and ALKPO 4 (55.86 IU/l vs. 60.97 IU/l, P = 0.205) enzyme levels between HIV-HBV co-infected and HIV mono-infected subjects albeit the two enzymes were moderately elevated in both categories of subjects. CONCLUSION The significantly elevated ALT enzyme levels amongst HIV-HBV co-infected subjects suggest that HIV-HBV co-infected patients may have an increased risk of liver-related morbidity and mortality than their HIV mono-infected counterparts. Screening for serological markers of chronic HBV infection, as well as hepatic transaminase enzyme levels in all newly diagnosed HIV-positive patients is therefore recommended before commencement of HAART.

Cryptococcal neorformans Antigenemiaamong HIV-Infected Patients in NorthEastern Nigeria

Background: Cryptococcus neoformans infection is a common fungal infection that is cosmopolitan in distribution and causes a life-threatening disease among HIV-infected patients especially in advanced disease. Screening for cryptococcal antigen (CrAg) in patients enrolling in ART programs may identify those at risk of cryptococcal meningitis and permit targeted use of pre-emptive therapy. Methods: This was a cross survey study of 215 consecutive HIV-infected patients at an ART treatment centre were screened for cryptococcal antigenaemia using the cryptococcalantigen lateral flow assay (CrAg LFA). Study subjects were assessed for clinical features of Cryptococcus neoformans infection. CD4+ cell count, haemoglobin concentration as well as HIV-1 RNA viral load was also compared between cryptococcalantigen positive and negatives. Results: 37 (16.7%) patients were positive for cryptococcal antigenaemia. Cryptococcal antigen positive subjects had a lower median CD4+ cell count (58 cells/uL vs. 273 cells/uL, p<0.001) and higher median viral load (log 3.6 copies/mL vs. log2.3 copies/mL, p=0.05) compared to cryptococcal antigen negative subjects. The commonest predictors of positive CrAg status in the study were; low BMI, low Hb, fever and cough. Conclusion: The study has shown the prevalence of cryptococcal antigenaemia to be high among the study subjects attending this service. Therefore, screening of patients receiving care at this centre may help in identifying individuals who are at risk of cryptococcalmeningitis for prophylactic treatment.

Extrapulmonary TB in North Eastern Nigeria: A 10-Year Retrospective Review

Background: Information on extrapulmonary TB is scarce in Nigeria despite being one of the 22 countries with highest burden of tuberculosis in the world and the most populous country in sub-Saharan Africa where the dual epidemics of TB and HIV/AIDS mutually co-exist. Objective: The purpose of this study was to document the burden of extrapulmonary TB in North-eastern Nigeria. Methodology: A retrospective cross-sectional study was conducted at a DOTS treatment centre in a tertiary hospital in North-eastern Nigeria. TB treatment registers and case records of 1240 patients were reviewed over a 10-year period. Results: Out of the 1240 TB cases who received treatment at the facility; 179 (14.4%) had extra-pulmonary TB. Skeletal TB and TB lymphadenitis were the predominant forms of extra-pulmonary TB in the study i.e. 51 (28.5%) and 50 (28.0%), respectively. This was closely followed by abdominal TB (38 (21.2%), tuberculous pleural effusion (23 (12.8%), miliary TB (9 (5.0%), TB meningitis (3 (1.7%) and others (5 (2.8%): viz; 1 (0.6%) each of- TB of the breast, TB of the skin, adrenal TB, genitourinary TB and TB pericarditis respectively. Only 101 (56.4%) of the study subjects had information on their HIV status; of whom 52 (51.5%) were HIV positive and 49 (48.5%) HIV negative. Conclusion: The study has shown that extrapulmonary TB was relatively common among TB patients receiving care at the facility despite its diagnostic challenges particularly in a resource poor setting like ours.